AbbVie News Center - News
3 days ago · Find out the latest news from AbbVie, a global biopharmaceutical company, including FDA approvals, clinical trials, earnings, and social impact. Browse by date, category, or keyword and follow AbbVie on social media.
AbbVie to Acquire ImmunoGen, including its Flagship Cancer ... - News
Nov 30, 2023 · AbbVie announced a definitive agreement to buy ImmunoGen, including its flagship cancer therapy ELAHERE, a first-in-class ADC for ovarian cancer. The transaction will expand AbbVie's oncology portfolio and pipeline across …
AbbVie to Acquire Landos Biopharma, Further Strengthening its ... - News
Mar 25, 2024 · AbbVie announces a definitive agreement to buy Landos, a biopharmaceutical company focused on oral therapies for autoimmune diseases. Landos' lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for ulcerative colitis and Crohn's disease.
AbbVie Tumbles After New Schizophrenia Drug Fails in Two Trials
3 days ago · AbbVie Inc. shares fell the most in more than four years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion ...
AbbVie raises 2024 profit forecast on strong sales of key drugs …
Oct 30 (Reuters) - AbbVie (ABBV.N) raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for...
AbbVie to Acquire Cerevel Therapeutics in Transformative …
Dec 6, 2023 · AbbVie will acquire Cerevel for $8.7 billion in cash, adding a portfolio of clinical-stage and preclinical candidates for psychiatric and neurological disorders. Cerevel's lead asset...
AbbVie Sees Higher Profits as New Drugs Offset Humira Decline
Jul 25, 2024 · AbbVie raised its full-year forecast for the two medicines by about $200 million combined. Humira sales were $2.8 billion, matching analysts’ projections. Once the world’s best-selling medicine,...
AbbVie Shares Slide, Bristol Myers Shares Rise After Schizophrenia ...
3 days ago · AbbVie said the schizophrenia drug candidate at the center of its recent $8.7 billion acquisition of Cerevel failed in a pair of mid-stage studies, sending the biopharmaceutical company's shares ...
ABBV.N - | Stock Price & Latest News | Reuters
Nov 7, 2024 · Get AbbVie Inc (ABBV.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments
AbbVie's Schizophrenia Failure Disappoints But Analysts Show …
1 day ago · On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. The ...
- Some results have been removed